1Kampo News: Special Edtion on Liver Health, 2003. Honso USA,Inc.
2Tianhan Xue. Letter to the Editor. Science, 2003, 300:2
3Ama S F, Lok. Chronic hepatitis B. Hepatology, December, 2001
4Zoli M. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. CAancer, 1996, 78:977～985
5Hopf U. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitisCvirus (HCV). J Hepatol, 1990, 10:69～76
6Di Bisceglie AM. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology, 1991, 14:969～974
7Tremolada F. Long-term follow-up of non-A, non-B (type C) posttransfusion hepatitis. J Hepatol, 1992, 16:273～281
8McHutchiso JG. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results druingtherapy. J Viral Hepat, 2001, 8:414～420
9Poynard T. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT), Lancetl,1998, 352: 1426～ 1432
10Manns MP. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial teratment of chronic hepatitis C:a randomised trial. Lancet, 2001, 358:958～965
